Regulatory News
Monday, November 7, 2016
BRIEF-Coherus Biosciences receives decision denying institution of '166 IPR related to AbbVie's Humira formulation
* Coherus biosciences receives decision denying institution
of the '166 IPR related to AbbVie's Humira formulation
Read more
No comments:
Post a Comment
‹
›
Home
View web version
No comments:
Post a Comment